Nektar Therapeutics
NASDAQ:NKTR

Watchlist Manager
Nektar Therapeutics Logo
Nektar Therapeutics
NASDAQ:NKTR
Watchlist
Price: 38.77 USD -2.37%
Market Cap: 788.6m USD

Wall Street
Price Targets

NKTR Price Targets Summary
Nektar Therapeutics

Wall Street analysts forecast NKTR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NKTR is 116.72 USD with a low forecast of 103.02 USD and a high forecast of 141.75 USD.

Lowest
Price Target
103.02 USD
166% Upside
Average
Price Target
116.72 USD
201% Upside
Highest
Price Target
141.75 USD
266% Upside
Nektar Therapeutics Competitors:
Price Targets
4016
Middle East Pharmaceutical Industries Company SJSC
12% Upside
PPLPHARMA
Piramal Pharma Ltd
47% Upside
SNT
Syntara Ltd
275% Upside
4521
Kaken Pharmaceutical Co Ltd
13% Upside
LUPIN
Lupin Ltd
6% Upside
216080
Jetema Co Ltd
36% Upside
688578
Shanghai Allist Pharmaceuticals Co Ltd
12% Upside

Revenue
Forecast

Revenue Estimate
Nektar Therapeutics

For the last 13 years the compound annual growth rate for Nektar Therapeutics's revenue is 2%. The projected CAGR for the next 4 years is -16%.

2%
Past Growth
-16%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Nektar Therapeutics

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-10%
Average Miss

Net Income
Forecast

Net Income Estimate
Nektar Therapeutics

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-52%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NKTR's stock price target?
Price Target
116.72 USD

According to Wall Street analysts, the average 1-year price target for NKTR is 116.72 USD with a low forecast of 103.02 USD and a high forecast of 141.75 USD.

What is Nektar Therapeutics's Revenue forecast?
Projected CAGR
-16%

For the last 13 years the compound annual growth rate for Nektar Therapeutics's revenue is 2%. The projected CAGR for the next 4 years is -16%.

Back to Top